Gilead Sales Up 18% in Q3, Thanks to Coronavirus Treatment Remdesivir
Gilead Sciences' (NASDAQ: GILD) product sales jumped 18% year over year in the third quarter thanks to its new coronavirus treatment, remdesivir, which goes by the brand name Veklury. Excluding the $873 million addition from remdesivir, sales would have been up a more modest 2%.
Remdesivir gained approval from the Food and Drug Administration last week, but the drug had previously been issued an emergency use authorization, which allowed Gilead to sell the antiviral drug.
Image source: Getty Images.
Source Fool.com
